deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test

Barcelona, Spain – 2 December 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its UllCORE Bloodstream Infection (BSI) Test.

The one hour, direct-from-blood test detects 95% of pathogens associated with bloodstream infections that may lead to sepsis, as well as select genetic determinants of antimicrobial resistance (AMR). The real-time multiplex PCR system extracts and analyzes total microbial DNA from 8 mL of whole blood, circumventing the lengthy and less sensitive blood culture process.

Jordi Carrera, Chief Executive Officer and Co-Founder of deepull, said: “We are thrilled to receive breakthrough designation from the FDA. Providing life-saving results for patients suspected of serious infection in one hour represents a significant advantage over current standard of care blood culture. Faster pathogen identification and AMR testing will provide clinicians with a powerful tool to more quickly and accurately tailor antimicrobial therapy, which could lead to faster patient recovery, shorter length of stay, and reduced morbidity and mortality.”

The FDA Breakthrough Devices Program is intended to provide patients with more timely access to innovative technologies that enable more effective treatment or diagnosis of life-threatening or irreversibly debilitating disease or conditions by supporting manufacturers to bring them to market faster.

Melissa Finocchio, deepull’s Chief Quality & Regulatory Officer, explained: “Early diagnosis is critical in the treatment of a multitude of infections but most notably for sepsis where standard blood culture testing takes days to deliver and often misses critical pathogens. This designation facilitates early feedback and interactive discussions between deepull and the FDA, allowing us to streamline our development and submission process.”

-Ends-

Notes to editors

About deepull

deepull is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx (sold to QIAGEN in 2018), deepull has assembled a team of world-class professionals to create rapid and accessible diagnostic solutions. Visit www.deepull.com for more information and follow us on LinkedIn.

deepull is developing the UllCORE BSI Test targeting 95% of sepsis-causing pathogens. The test extracts total microbial DNA from 8mL of whole blood and includes 52 reportable results. The test runs on the deepull UllCORE analyzer; a benchtop system with sample-to-result automation designed to meet the needs of any hospital clinical laboratory.

For more information, please contact:

deepull

Agustina Boullaude

Email: aboullaude@deepull.com

ICR Healthcare

Amber Fennell / Lucy Featherstone

Email: deepull@icrhealthcare.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.